BARDA Expands US Domestic Production Of Single-Use Systems For Vaccine Manufacturing
Executive Summary
FlexBiosys wins award; others to follow. New capacity may also benefit manufacture of monoclonal antibodies and cell and gene therapies.
You may also be interested in...
US Supply Chain In Brief: White House Aims To Deliver With Block Stowing And Industrial Base Expansion
Biden administration works to expedite medical supplies and expand medical countermeasures production, while US FDA's DSCSA anti-counterfeiting paperwork burden estimate surges.
Communication Is Key In Adapting Production To Pandemic Component Supply Disruptions
US FDA is looking at risk-based approach for reporting changes in out-of-stock components such as plastic bioreactor bags, filters and tubing sets that are in short supply.
Time Is Now To Seek US Funding, Financing To Expand Domestic COVID-19 Vaccine Supply Chain
BARDA and Development Financing Corp. officials provide insights into window of opportunity for partnering on manufacturing scale-up.